TOPAZ-1: a new standard of care for advanced biliary tract cancers?

ImmunotherapyVol. 15, No. 7 EditorialTOPAZ-1: a new standard of care for advanced biliary tract cancers?Matthew I Ebia, Kamya Sankar, Arsen Osipov, Andrew E Hendifar & Jun GongMatthew I Ebia https://orcid.org/0000-0001-7159-1926Department of Medicine, Division of Hematology & Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USASearch for more papers by this author, Kamya SankarDepartment of Medicine, Division of Hematology & Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USACedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA 90048, USASearch for more papers by this author, Arsen OsipovDepartment of Medicine, Division of Hematology & Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USACedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA 90048, USASearch for more papers by this author, Andrew E HendifarDepartment of Medicine, Division of Hematology & Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USACedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA 90048, USASearch for more papers by this author & Jun Gong*Author for correspondence: E-mail Address: jun.gong@cshs.orgDepartment of Medicine, Division of Hematology & Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USACedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA 90048, USASearch for more papers by this authorPublished Online:23 Mar 2023https://doi.org/10.2217/imt-2022-0269AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: biliary tract cancercancer survivalcheckpoint inhibitorschemotherapycholangiocarcinomaReferences1. Banales JM, Marin JJG, Lamarca A et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17(9), 557–588 (2020).Crossref, Medline, Google Scholar2. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273–1281 (2010).Crossref, Medline, CAS, Google Scholar3. Oh D-Y, He AR, Qin S et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence 1(8), EVIDoa2200015 (2022).Crossref, Google Scholar4. Burns HA 3rd, Okusaka T, Vogel A et al. Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. J. Clin. Oncol. 40(Suppl.16), 4070 (2022).Google Scholar5. Vogel A, Boeck S, Waidmann O et al. 52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC). Ann. Oncol. 33, S563 (2022).Medline, Google Scholar6. Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin. Investig. Drugs 30(4), 343–350 (2021).Crossref, Medline, CAS, Google Scholar7. Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box? ESMO Open 5(5), e001042 (2020).Crossref, Medline, Google Scholar8. Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018).Crossref, Medline, CAS, Google Scholar9. Gadgeel S, Rodriguez-Abreu D, Speranza G et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 38(14), 1505–1517 (2020).Crossref, Medline, CAS, Google Scholar10. Burtness B, Harrington KJ, Greil R et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212), 1915–1928 (2019).Crossref, Medline, CAS, Google Scholar11. Harrington KJ, Burtness B, Greil R et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J. Clin. Oncol. 41(4), 790–802 (2022).Crossref, Medline, Google Scholar12. Powles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383(13), 1218–1230 (2020).Crossref, Medline, CAS, Google Scholar13. Sahai V, Griffith KA, Beg MS et al. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer 128(19), 3523–3530 (2022).Crossref, Medline, CAS, Google Scholar14. Shroff RT, Guthrie KA, Scott AJ et al. SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J. Clin. Oncol. 41(Suppl. 4), LBA490–LBA490 (2023).Google Scholar15. Shroff RT, Javle MM, Xiao L et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 5(6), 824–830 (2019).Crossref, Medline, Google Scholar16. Schizas D, Mastoraki A, Routsi E et al. Combined hepatocellular-cholangiocarcinoma: an update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat. Dis. Int. 19(6), 515–523 (2020).Crossref, Medline, Google Scholar17. Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894–1905 (2020).Crossref, Medline, CAS, Google Scholar18. Nguyen CT, Caruso S, Maille P et al. Immune profiling of combined hepatocellular-cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. Clin. Cancer Res. 28(3), 540–551 (2022).Crossref, Medline, CAS, Google Scholar19. Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers (Basel) 12(8), 2039 (2020).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 15, No. 7 STAY CONNECTED Metrics Downloaded 144 times History Received 25 October 2022 Accepted 14 February 2023 Published online 23 March 2023 Published in print May 2023 Information© 2023 Future Medicine LtdKeywordsbiliary tract cancercancer survivalcheckpoint inhibitorschemotherapycholangiocarcinomaAuthor contributionsM Ebia contributed to the writing, original draft preparation, reviewing and editing. K Sankar contributed to writing, reviewing and editing. A Osipov contributed to writing, reviewing and editing. A Hendifar contributed to writing, reviewing and editing. J Gong contributed to conceptualization, writing, reviewing and editing.Financial & competing interests disclosureJ Gong is a consultant or has an advisory role for the following institutions; EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Myovant, Astellas and Amgen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download